Contents

Volume 82 Issue 8 | ARD August 2023

Review
999  Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets
M K Crow

1015  ChatGPT: when artificial intelligence replaces the rheumatologist in medical writing
F Verhoeven, D Wendling, C Prati

Rheumatoid arthritis
1018  Country-level socioeconomic status relates geographical latitude to the onset of RA: a worldwide cross-sectional analysis in the METEOR registry

1025  Irreversible covalent Bruton’s tyrosine kinase inhibitor, TASS315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIIa trial
T Takeuchi, S Tanaka, M Murata, Y Tanaka

1035  Identification of MYH3 as a key regulator for synoviocyte migration and invasion through secretome profiling
S Lee, E Choi, S Chae, J H Koh, Y Choi, J G Kim, S-A You, D Hwang, W-U Kim

Treatment
1049  Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-Ray studies

1059  JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications
M D Russell, C Stovin, E Alvey, O Adeyemi, C K D Chan, V Patel, M A Adams, F Azzeni, K K H Ng, A I Rutherford, S Norton, A P Cope, J B Galloway

1068  Is methotrexate safe for men with an immune-mediated inflammatory disease and an active desire to become a father? Results of a prospective cohort study (iFAME-MTX)

Spondyloarthritis
1076  Distinct immune modulatory roles of regulatory T cells in gut versus joint inflammation in TNF-driven spondyloarthritis

Myositis
1091  Transcriptional derepression of CHD4/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies

Disclaimer: The Editor of ARD has been granted editorial freedom and ARD is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. ARD is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by ARD does not imply endorsement. Neither EULAR nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage whatsoever arising from ARD (except for liability which cannot be legally excluded).

Copyright: © 2023 BMJ Publishing Group Ltd and European Alliance of Associations for Rheumatology. All rights reserved: no part of this publication may be reproduced in any form without permission.
ARD is published by BMJ Publishing Group Ltd, typestyle by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.
Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 83rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256, US Postmaster: Send address changes to Annals of the Rheumatic Diseases, World Container Inc, 150-15, 83rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.
### Contents

#### Vascularitis

1098 Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients


---

#### Education

1107 Points to consider: EULAR–UEMS standards for the training of European rheumatologists


---

#### Images in rheumatology

1114 Homonymous hemianopsia and headache with mass-like lesion

K Aso, Y Fujieda, T Asumi

---

#### Letters

1116 High frequency of long-term opioid use among patients with rheumatic and musculoskeletal diseases initiating opioids for the first time

Y-T Huang, D A Jenkins, N Peck, W G Dixon, M Jani

---

1117 Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells


---

1120 Familial systemic lupus erythematosus associated with a loss-of-function mutation in TRPC6

D Chen, H Yin, L Zhang, F Li, I Lu

---

#### Electronic pages

e177 Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry”

R F van Vollenhoven, S W Tas, M T Nurrohmaned

e178 Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis” by van Vollenhoven et al

J A Sparks, Z S Wallace, A M Seet, P C Robinson, P M Machado, J Yazdany

e179 Correspondence on Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients

Y Liu

---

178 Response to: Correspondence on ‘Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients’ by Liu

M J Fritts, U Tramserberg, on behalf of the COVID-19 Longitudinal Biomarkers of Lung Injury (COBOLIL) study group

---

e181 Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: a missed ‘window of opportunity’

A Ciesla, R Bisco, D Catti, O Visani, I Idiacci, C Deiaco, M Rossini

---

e182 Correspondence on ‘Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: case–control study’

M S Winkler, P Grosten, R Buder, B Timpe

---

e183 Correspondence on ‘Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C-reactive protein level and patient global assessment’

R J O Ferreira, P J Welsing, J WC Jacob, L Gosec, M Nédou, P M Machado, D van der Heide, J AP da Silva

---

e184 Response to: Correspondence on ‘Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C-reactive protein level and patient global assessment’ by Ferreira et al

D Felson, D Lacaille, M P LaValley, D Alethea

---

e185 Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’

S Siebert, H Marzo-Ortega

---

e186 Response to: Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Siebert and Marzo-Ortega

J Brawn, R BM Landewe
e187 Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’

e188 Response to: Correspondence on ‘No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?’ by Gladman
R BM Landewé, J Braun

e189 Correspondence on “New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE”
G J Pons-Estel, M F Ugarte-Gil, G B Harvey, B A Pons-Estel, G S Alarcón

e190 Response to: Correspondence on “New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE” by Pons-Estel et al
I. Whittall-García, D D Gladman, M Urowitz, J Su, Z Touma, S R Johnson

e191 Correspondence on “Update on the diagnosis and management of systemic lupus erythematosus”
Z Zhou, Y You, F Wang, Y Sun, J Teng, H Liu, X Cheng, Y Su, H Shi, C Yang, J Ye

e192 Response to: Correspondence on “Update on the diagnosis and management of systemic lupus erythematosus” by Zhou et al
A Fanouridakis, N Tezios, G Bertsias, D T Bourspas

e193 Correspondence on “European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance”
X Bossuyt, W Fierez, P L Meroni

e194 Response to: Correspondence on “European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance” by Bossuyt et al
M Aringer, K Costenbader, N Leuchtten, T Dönner, S R Johnson

e195 Correspondence on ‘Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors’
D Patoulis

e196 Response to: Correspondence on ‘Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors’ by Patoulis
M Szémann, A Kronbichler

e197 Correspondence on ‘2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis’ by Joanna C Robson et al and ‘2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis’
V R Pimentel-Quiroz, M F Ugarte-Gil, G S Alarcón

e198 Response to: Correspondence on ‘2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis’ by Joanna C Robson et al and ‘2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis’ by Pimentel-Quiroz et al
P C Grayson, J C Robson, R Suppiah, C Ponte, R A Watts, R A Luqmani, P A Merkel

e199 Where are the women ‘Heroes and Pillars of Rheumatology’?
N Dalénk, T Ntogi

e200 Response to: Where are the women ‘Heroes and Pillars of Rheumatology’?
J S Smolen